

1. Ferlay JB, Parkin F, Pisani DMP, eds. *Cancer Incidence and Mortality Worldwide*. ISRC Cancer Bases No. 5; 2001, 2000.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin* 2011;61:69–90.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. *CA Cancer J Clin* 2009;59:225–249.
4. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64:9–29.
5. Anderson WF, Fraumeni FJ, Rosenberg PS, et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. *JAMA* 2010;303:1723–1728.
6. Keeney S, Baur TL. Epidemiology of adenocarcinoma of the esophagogastric junction. *Surg Oncol Clin N Am* 2006;15:687–696.
7. Pacelli F, Cusumano G, Marrelli D, et al. Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. *JAMA Surg* 2013;148:353–360.
8. Lewin JKA. Gastrointestinal tract: stomach. In: Juan R, editor. *Surgical Pathology*. Maryland Heights, MO: Mosby, 2004.
9. Zullo A, Hassan C, Andriani A, et al. Eradication therapy for *Helicobacter pylori* in patients with gastric MALT lymphoma: a pooled data analysis. *Am J Gastroenterol* 2009;104:1932–1937, quiz 1938.
10. Luminari S, Cesaretti M, Marcheselli L, et al. Decreasing incidence of gastric MALT lymphomas in the era of anti-*Helicobacter pylori* interventions: results from a population-based study on extranodal marginal zone lymphomas. *Ann Oncol* 2010;21:855–859.
11. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. *Science* 2004;306:1568–1571.
12. Stoicov C, Saffari R, Cai X, et al. Molecular biology of gastric cancer: *Helicobacter* infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. *Gene* 2004;341:1–17.
13. Stoicov C, Li H, Carlson J, et al. Bone marrow cells as the origin of stomach cancer. *Future Oncol* 2005;1:851–862.
14. Li HC, Stoicov C, Rogers AB, et al. Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers. *World J Gastroenterol* 2006;12:363–371.
15. Avital I, Moreira AL, Klimstra DS, et al. Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. *Stem Cells* 2007;25:2903–2909.
16. Saikawa Y, Fukuda K, Takahashi T, et al. Gastric carcinogenesis and the cancer stem cell hypothesis. *Gastric Cancer* 2010;13:11–24.
17. Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. *Stem Cells* 2009;27:1006–1020.
18. The general rules for The gastric cancer study in surgery. *Jpn J Surg* 1973;3:61–71.
19. Ming SC. The classification and significance of gastric polyps. *Monogr Pathol* 1977;(18):149–175.
20. Bearzi I, Ranaldi R. Early gastric cancer: a morphologic study of 41 cases. *Tumori* 1982;68:223–233.
21. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965;64:31–49.
22. Machado JC, Soares P, Carneiro F, et al. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. *Lab Invest* 1999;79:459–465.
23. Soga K, Ichikawa D, Yasukawa S, et al. Prognostic impact of the width of subserosal invasion in gastric cancer invading the subserosal layer. *Surgery* 2010;147:197–203.
24. Zinninger MM. Extension of gastric cancer in the intramural lymphatics and its relation to gastrectomy. *Am Surg* 1954;20:920–927.
25. Zinninger MM, Collins WT. Extension of Carcinoma of the Stomach into the Duodenum and Esophagus. *Ann Surg* 1949;130:557–566.
26. Kakeji Y, Tsujitani S, Baba H, et al. Clinicopathologic features and prognostic significance of duodenal invasion in patients with distal gastric carcinoma. *Cancer* 1991;68:380–384.
27. Nogueira AM, Silva AC, Paiva EB, et al. [Distal gastric carcinoma with duodenal invasion: histopathologic study and review of the literature]. *Arq Gastroenterol* 2000;37:168–173.
28. Barbour AP, Rizk NP, Gonen M, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. *Ann Surg* 2007;246:1–8.
29. Miyazaki M, Itoh H, Nakagawa K, et al. Hepatic resection of liver metastases from gastric carcinoma. *Am J Gastroenterol* 1997;92:490–493.
30. Kim JP, Lee JH, Kim SJ, et al. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. *Gastric Cancer* 1998;1:125–133.
31. D'Angelica M, Gonen M, Brennan MF, et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. *Ann Surg* 2004;240:808–816.
32. Namieno T, Koito K, Higashi T, et al. General pattern of lymph node metastasis in early gastric carcinoma. *World J Surg* 1996;20:996–1000.
33. Mariyama K, Gunvén P, Okabayashi K, et al. Lymph node metastases of gastric cancer. General pattern in 1931 patients. *Ann Surg* 1989;210:596–602.
34. Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. *Br J Surg* 2000;87:236–242.
35. Zacherl J, Zacherl M, Scheuba C, et al. Analysis of hepatic resection of metastasis originating from gastric adenocarcinoma. *J Gastrointest Surg* 2002;6:682–689.
36. Sakamoto Y, Ohyama S, Yamamoto J, et al. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. *Surgery* 2003;133:507–511.
37. Classic articles in colonic and rectal surgery. George Blumer, M.D.: The rectal shelf. *Dis Colon Rectum* 1980;23(6):445.
38. Kong SH, Park DJ, Lee HJ, et al. Clinicopathologic features of asymptomatic gastric adenocarcinoma patients in Korea. *Jpn J Clin Oncol* 2004;34:1–7.
39. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. *Ann Surg* 1993;218:583–592.
40. Maconi G, Manes G, Porro GB. Role of symptoms in diagnosis and outcome of gastric cancer. *World J Gastroenterol* 2008;14:1149–1155.
41. Axon A. Symptoms and diagnosis of gastric cancer at early curable stage. *Best Pract Res Clin Gastroenterol* 2006;20:697–708.
42. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. *Am J Med* 1980;69:491–497.
43. Kahrilas PJ, Kishk SM, Helm JF, et al. Comparison of pseudoachalasia and achalasia. *Am J Med* 1987;82:439–446.
44. Gilliland R, Gill PJ. Incidence and prognosis of Krukenberg tumour in Northern Ireland. *Br J Surg* 1992;79:1364–1366.
45. Morgenstern L. The Virchow-Troisier node: a historical note. *Am J Surg* 1979;138:703.
46. Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. *J Gastroenterol* 2010;45:1–8.
47. Ruge M, Kim JG, Mahachai V, et al. OLGa gastritis staging in young adults and country-specific gastric cancer risk. *Int J Surg Pathol* 2008;16:150–154.
48. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with *Helicobacter pylori* infection increases risk of gastric cancer. *Int J Cancer* 2004;109:138–143.
49. Watabe H, Mitsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining *Helicobacter pylori* antibodies and serum pepsinogen status: a prospective endoscopic cohort study. *Gut* 2005;54:764–768.
50. Yoshihara M, Sumii K, Haruma K, et al. Correlation of ratio of serum pepsinogen I and II with prevalence of gastric cancer and adenoma in Japanese subjects. *Am J Gastroenterol* 1998;93:1090–1096.
51. Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends *Helicobacter pylori* screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. *Am J Gastroenterol* 2008;103:510–514.
52. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. *Lancet Oncol* 2008;9:279–287.
53. Parsonnet J, Harris RA, Hack HM, et al. Modelling cost-effectiveness of *Helicobacter pylori* screening to prevent gastric cancer: a mandate for clinical trials. *Lancet* 1996;348:150–154.
54. Roderick P, Davies R, Rafferty J, et al. Cost-effectiveness of population screening for *Helicobacter pylori* in preventing gastric cancer and peptic ulcer disease, using simulation. *J Med Screen* 2003;10:148–156.
55. Mason J, Axon AT, Forman D, et al. The cost-effectiveness of population *Helicobacter pylori* screening and treatment: a Markov model using economic data from a randomized controlled trial. *Aliment Pharmacol Ther* 2002;16:559–568.
56. Marrelli D, Roviello F, De Stefano A, et al. Prognostic significance of CEA, CA 19-9 and CA 72-4 preoperative serum levels in gastric carcinoma. *Oncology* 1999;57:55–62.
57. Nakane Y, Okamura S, Akehira K, et al. Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. *Cancer* 1994;73:2703–2708.
58. Yehou M, Duffour J, Kramar A, et al. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. *Dis Markers* 2000;16:105–110.
59. Pectasides D, Mylonakis A, Kostopoulou M, et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. *Am J Clin Oncol* 1997;20:348–353.
60. Kodera Y, Yamamura Y, Torii A, et al. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. *Am J Gastroenterol* 1996;91:49–53.
61. Kochi M, Fujii M, Kanamori N, et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. *Gastric Cancer* 2000;3:177–186.
62. Park SH, Ku KB, Chung HY, et al. Prognostic significance of serum and tissue carcinoembryonic antigen in patients with gastric adenocarcinomas. *Cancer Res Treat* 2008;40:16–21.
63. Liu H, Li YQ, Yu T, et al. Confocal endomicroscopy for in vivo detection of microvascular architecture in normal and malignant lesions of upper gastrointestinal tract. *J Gastroenterol Hepatol* 2008;23:56–61.
64. Hyatt BJ, Paull PE, Wassef W. Gastric oncology: an update. *Curr Opin Gastroenterol* 2009;25:570–578.
65. Kwee RM, Kwee TC. Imaging in local staging of gastric cancer: a systematic review. *J Clin Oncol* 2007;25:2107–2116.

66. Bentrem D, Gerdes H, Tang L, et al. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. *Ann Surg Oncol* 2007;14:1853–1859.
67. Hwang SW, Lee DH, Lee SH, et al. Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. *J Gastroenterol Hepatol* 2010;25:512–518.
68. Yan C, Zhu ZG, Yan M, et al. Value of multidetector-row computed tomography in the preoperative T and N staging of gastric carcinoma: a large-scale Chinese study. *J Surg Oncol* 2009;100:205–214.
69. Chen CY, Hsu JS, Wu DC, et al. Gastric cancer: preoperative local staging with 3D multi-detector row CT—correlation with surgical and histopathologic results. *Radiology* 2007;242:472–482.
70. Anzidei M, Napoli A, Zaccagna F, et al. Diagnostic performance of 64-MDCT and 1.5-T MRI with high-resolution sequences in the T staging of gastric cancer: a comparative analysis with histopathology. *Radiol Med* 2009;114:1065–1079.
71. Sohn KM, Lee JM, Lee SY, et al. Comparing MR imaging and CT in the staging of gastric carcinoma. *AJR Am J Roentgenol* 2000;174:1551–1557.
72. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. *Cancer* 2001;92:634–641.
73. Dassen AE, Lips DJ, Hoekstra CJ, et al. FDG-PET has no definite role in preoperative imaging in gastric cancer. *Eur J Surg Oncol* 2009;35:449–455.
74. Chen J, Cheong JH, Yun MJ, et al. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. *Cancer* 2005;103:2383–2390.
75. Yang QM, Kawamura T, Itoh H, et al. Is PET-CT suitable for predicting lymph node status for gastric cancer? *Hepatogastroenterology* 2008;55:782–785.
76. Yun M, Lim JS, Noh SH, et al. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. *J Nucl Med* 2005;46:1582–1588.
77. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. *J Clin Oncol* 2003;21:4604–4610.
78. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. *Lancet Oncol* 2007;8:797–805.
79. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. *Gastric Cancer* 2009;12:6–22.
80. Kim EY, Lee WJ, Choi D, et al. The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast-enhanced CT. *Eur J Radiol* 2011;79:183–188.
81. Smyth E, Schöder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. *Cancer* 2012;118:5481–5488.
82. Goldfarb M, Brower S, Schwaartzberg SD. Minimally invasive surgery and cancer: controversies part 1. *Surg Endosc* 2010;24:304–334.
83. Conlon KC. Staging laparoscopy for gastric cancer. *Ann Ital Chir* 2001;72:33–37.
84. Burke EC, Karpeh MS, Conlon KC, et al. Laparoscopy in the management of gastric adenocarcinoma. *Ann Surg* 1997;225:262–267.
85. Sarella AI, Lefkowitz R, Brennan MF, et al. Selection of patients with gastric adenocarcinoma for laparoscopic staging. *Am J Surg* 2006;191:134–138.
86. Tirindelli Danesi D, Cucchiara G, Picconi A, et al. Retrospective analysis of the prognostic significance of DNA ploidy patterns in gastric cancer. *Eur J Histochem* 1997;41:147–148.
87. Muntean V, Mihailev A, Iancu C, et al. Staging laparoscopy in gastric cancer. Accuracy and impact on therapy. *J Gastrointest Liver Dis* 2009;18:189–195.
88. Lehnert T, Rudek B, Kienle P, et al. Impact of diagnostic laparoscopy on the management of gastric cancer: prospective study of 120 consecutive patients with primary gastric adenocarcinoma. *Br J Surg* 2002;89:471–475.
89. Blackshaw GR, Barry JD, Edwards P, et al. Laparoscopy significantly improves the perceived preoperative stage of gastric cancer. *Gastric Cancer* 2003;6:225–229.
90. Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. *Ann Surg Oncol* 2005;12:347–353.
91. Dalal KM, Woo Y, Kelly K, et al. Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. *Gastric Cancer* 2008;11:206–213.
92. Wilkemyer MB, Bieligg SC, Ashfaq R, et al. Laparoscopy alone is superior to peritoneal cytology in staging gastric and esophageal carcinoma. *Surg Endosc* 2004;18:852–856.
93. Nakagawa S, Nashimoto A, Yabusaki H. Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer. *Gastric Cancer* 2007;10:29–34.
94. Wong J, Schulman A, Kelly K, et al. Detection of free peritoneal cancer cells in gastric cancer using cancer-specific Newcastle disease virus. *J Gastrointest Surg* 2010;14:7–14.
95. Smith A, Finch MD, John TG, et al. Role of laparoscopic ultrasonography in the management of patients with oesophagogastric cancer. *Br J Surg* 1999;86:1083–1087.
96. Lavonius MI, Gullichsen R, Salo S, et al. Staging of gastric cancer: a study with spiral computed tomography, ultrasonography, laparoscopy, and laparoscopic ultrasonography. *Surg Laparosc Endosc Percutan Tech* 2002;12:77–81.
97. Hulscher JB, Nieveen van Dijkum EJ, de Wit LT, et al. Laparoscopy and laparoscopic ultrasonography in staging carcinoma of the gastric cardia. *Eur J Surg* 2000;166:862–865.
98. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer Staging Manual and the future of TNM. *Ann Surg Oncol* 2010;17:1471–1474.
99. Karpeh MS, Leon L, Klimstra D, et al. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. *Ann Surg* 2000;232:362–371.
100. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. *J Clin Oncol* 2005;23:7114–7124.
101. Ichikura T, Tomimatsu S, Uefuji K, et al. Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. *Cancer* 1999;86:553–558.
102. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. *Ann Surg Oncol* 2007;14:317–328.
103. Kattan MW, Karpeh MS, Mazumdar M, et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. *J Clin Oncol* 2003;21:3647–3650.
104. Ichikura T, Ogawa T, Chochi K, et al. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma. *World J Surg* 2003;27:330–333.
105. Aurello P, D'Angelo F, Rossi S, et al. Classification of lymph node metastases from gastric cancer: comparison between N-site and N-number systems. Our experience and review of the literature. *Am Surg* 2007;73:359–366.
106. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. *Cancer* 2000;88:921–932.
107. Bando E, Yonemura Y, Taniguchi K, et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. *Ann Surg Oncol* 2002;9:775–784.
108. Sun Z, Zhu GL, Lu C, et al. The impact of N-ratio in minimizing stage migration phenomenon in gastric cancer patients with insufficient number or level of lymph node retrieved: results from a Chinese mono-institutional study in 2159 patients. *Ann Oncol* 2009;20:897–905.
109. Huang CM, Lin JX, Zheng CH, et al. Prognostic impact of metastatic lymph node ratio on gastric cancer after curative distal gastrectomy. *World J Gastroenterol* 2010;16:2055–2060.
110. Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. *Ann Surg Oncol* 2002;9:27–34.
111. Xu DZ, Geng QR, Long ZJ, et al. Positive lymph node ratio is an independent prognostic factor in gastric cancer after d2 resection regardless of the examined number of lymph nodes. *Ann Surg Oncol* 2009;16:319–326.
112. Sun Z, Xu Y, Li de M, et al. Log odds of positive lymph nodes: a novel prognostic indicator superior to the number-based and the ratio-based N category for gastric cancer patients with R0 resection. *Cancer* 2010;116:2571–2580.
113. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition. *Gastric Cancer* 1998;1:10–24.
114. Kurihara M, Aiko T. The new Japanese classification of gastric carcinoma: revised explanation of “response assessment of chemotherapy and radiotherapy for gastric carcinoma.” *Gastric Cancer* 2001;4:9–13.
115. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma—2nd English edition—response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. *Gastric Cancer* 2001;4:1–8.
116. Aikou T, Hokita S, Natsugoe S. [Japanese Classification of Gastric Carcinoma (the 13th edition, June 1999): points to be revised]. *Nippon Rinsho* 2001;59:159–165.
117. Sayegh ME, Sano T, Dexter S, et al. TNM and Japanese staging systems for gastric cancer: how do they coexist? *Gastric Cancer* 2004;7:140–148.
118. Aiko T, Sasako M. The new Japanese Classification of Gastric Carcinoma: Points to be revised. *Gastric Cancer* 1998;1:25–30.
119. Zhang M, Zhu G, Ma Y, et al. Comparison of four staging systems of lymph node metastasis in gastric cancer. *World J Surg* 2009;33:2383–2388.
120. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. *Br J Surg* 1998;85:1457–1459.
121. Siewert JR, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1002 consecutive patients. *Ann Surg* 2000;232:353–361.
122. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. *Surg Oncol Clin N Am* 2006;15:751–764.
123. Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. *Semin Surg Oncol* 1994;10:12–20.
124. Peeters KC, Kattan MW, Hartgrink HH, et al. Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. *Cancer* 2005;103:702–707.

125. Novotny AR, Schuhmacher C, Busch R, et al. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. *Ann Surg* 2006;243:74–81.
126. Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. *Ann Surg* 2010;251:640–646.
127. Han MA, Oh MG, Choi JJ, et al. Association of family history with cancer recurrence and survival in patients with gastric cancer. *J Clin Oncol* 2012;31:701–708.
128. Nishi M, Omori Y, Miwa K, eds. *Japanese Research Society for Gastric Cancer. Japanese Classification Of Gastric Carcinoma*. Kanehara, Tokyo: 1995:73.
129. Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. *Lancet* 1997;349:1725–1729.
130. Gotoda T, Yanagisawa A, Sasako M, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. *Gastric Cancer* 2000;3:219–225.
131. Kwee RM, Kwee TC. Predicting lymph node status in early gastric cancer. *Gastric Cancer* 2008;11:134–148.
132. Haruta H, Hosoya Y, Sakuma K, et al. Clinicopathological study of lymph-node metastasis in 1389 patients with early gastric cancer: assessment of indications for endoscopic resection. *J Dig Dis* 2008;9:213–218.
133. Jeong O, Ryu SY, Park YK. Accuracy of surgical diagnosis in detecting early gastric cancer and lymph node metastasis and its role in determining limited surgery. *J Am Coll Surg* 2009;209:302–307.
134. Li H, Lu P, Lu Y, et al. Predictive factors of lymph node metastasis in undifferentiated early gastric cancers and application of endoscopic mucosal resection. *Surg Oncol* 2010;19:221–226.
135. Park JM, Kim SW, Nam KW, et al. Is it reasonable to treat early gastric cancer with signet ring cell histology by endoscopic resection? Analysis of factors related to lymph-node metastasis. *Eur J Gastroenterol Hepatol* 2009;21:1132–1135.
136. Hirasawa T, Gotoda T, Miyata S, et al. Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. *Gastric Cancer* 2009;12:148–152.
137. Holscher AH, Drebber U, Mönig SP, et al. Early gastric cancer: lymph node metastasis starts with deep mucosal infiltration. *Ann Surg* 2009;250:791–797.
138. Matsumoto M, Natsugoe S, Ishigami S, et al. Lymph node micrometastasis and lymphatic mapping determined by reverse transcriptase-polymerase chain reaction in pN0 gastric carcinoma. *Surgery* 2002;131:630–635.
139. Bennett C, Wang Y, Pan T. Endoscopic mucosal resection for early gastric cancer. *Cochrane Database Syst Rev* 2009;(4):CD004276.
140. Jee YS, Hwang SH, Rao J, et al. Safety of extended endoscopic mucosal resection and endoscopic submucosal dissection following the Japanese Gastric Cancer Association treatment guidelines. *Br J Surg* 2009;96:1157–1161.
141. Kojima T, Parra-Blanco A, Takahashi H, et al. Outcome of endoscopic mucosal resection for early gastric cancer: review of the Japanese literature. *Gastrointest Endosc* 1998;48:550–554, discussion 554–555.
142. Giovannini M, Bernardini D, Moutardier V, et al. Endoscopic mucosal resection (EMR): results and prognostic factors in 21 patients. *Endoscopy* 1999;31:698–701.
143. Oda I, Saito D, Tada M, et al. A multicenter retrospective study of endoscopic resection for early gastric cancer. *Gastric Cancer* 2006;9:262–270.
144. Yokoi C, Gotoda T, Hamanaka H, et al. Endoscopic submucosal dissection allows curative resection of locally recurrent early gastric cancer after prior endoscopic mucosal resection. *Gastrointest Endosc* 2006;64:212–218.
145. Ida K, Nakazawa S, Yoshino J, et al. Multicenter collaborative prospective study of endoscopic treatment of early gastric cancer. *Dig Endos* 2004;16:295–302.
146. Nelson DB, Block KP, Bosco JJ, et al. Technology status evaluation report: computerized endoscopic medical record systems: November 1999. *Gastrointest Endosc* 2000;51:793–796.
147. Noda M, Kodama T, Atsumi M, et al. Possibilities and limitations of endoscopic resection for early gastric cancer. *Endoscopy* 1997;29:361–365.
148. Tanabe S, Koizumi W, Kokutou M, et al. Usefulness of endoscopic aspiration mucosectomy as compared with strip biopsy for the treatment of gastric mucosal cancer. *Gastrointest Endosc* 1999;50:819–822.
149. Oizumi H. Endoscopic resection for early gastric cancer. *Stomach & Intestine* 1991;26:289.
150. Watanabe Y, Kato N, Maehata T, et al. Safer endoscopic gastric mucosal resection: preoperative proton pump inhibitor administration. *J Gastroenterol Hepatol* 2006;21:1675–1680.
151. Fukase K, Matsuda T, Suzuki M, et al. Evaluation of the efficacy of endoscopic treatment for gastric cancer considered in terms of long-term prognosis. A comparison with surgical treatment. *Digestive Endoscopy* 1994;6:241–247.
152. Fukase K, Kawata S. Evaluation of the efficacy of endoscopic treatment for early gastric cancer considered in terms of long-term prognosis more than 10 years — a comparison with surgical treatment. *Yamagata Med J* 2004;22:1.
153. Park IS, Lee YC, Kim WH, et al. Clinicopathologic characteristics of early gastric cancer in Korea. *Yonsei Med J* 2000;41:607–614.
154. Kim HS, Lee DK, Baik SK, et al. Endoscopic mucosal resection with a ligation device for early gastric cancer and precancerous lesions: comparison of its therapeutic efficacy with surgical resection. *Yonsei Med J* 2000;41:577–583.
155. Takekoshi T, Baba Y, Ota H, et al. Endoscopic resection of early gastric carcinoma: results of a retrospective analysis of 308 cases. *Endoscopy* 1994;26:352–358.
156. Chonan A, Mochizuki F, Ando M, et al. Endoscopic ultrasonography for the diagnosis of gastric malignant lymphoma. *Endoscopy* 1998;30:A76–A77.
157. Hiki Y, Sakakibara Y, Mieno H, et al. Endoscopic treatment of gastric cancer. *Surg Endosc* 1991;5:11–13.
158. Kondo H, Gotoda T, Ono H, et al. Early gastric cancer: endoscopic mucosal resection. *Ann Ital Chir* 2001;72:27–31.
159. Ono H, Kondo H, Gotoda T, et al. Endoscopic mucosal resection for treatment of early gastric cancer. *Gut* 2001;48:225–229.
160. Tada M, Tokiyama H, Nakamura H, et al. Endoscopic resection for early gastric cancer. *Acta Endoscopica* 1998;28:87–95.
161. Tada M, Matsumoto Y, Murakami A, et al. Problems and their solutions in curative endoscopic resection of early gastric carcinomas. *Endosc Digest* 1993;5:1169–1174.
162. Park JC, Lee SK, Seo JH, et al. Predictive factors for local recurrence after endoscopic resection for early gastric cancer: long-term clinical outcome in a single-center experience. *Surg Endosc* 2010;24:2842–2849.
163. Nakamoto S, Sakai Y, Kasanuki J, et al. Indications for the use of endoscopic mucosal resection for early gastric cancer in Japan: a comparative study with endoscopic submucosal dissection. *Endoscopy* 2009;41:746–750.
164. Tomita R, Fujisak S, Park YJ. Mini-laparotomy with abdominal wall lifting for partial gastrectomy in patients with early gastric mucosal cancer at lesser curvature of the middle stomach. *Hepatogastroenterology* 2009;56:1768–1772.
165. Yamaguchi N, Isomoto H, Fukuda E, et al. Clinical outcomes of endoscopic submucosal dissection for early gastric cancer by indication criteria. *Digestion* 2009;80:173–181.
166. Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. *Ann Surg* 1989;209:162–166.
167. Robertson CS, Chung SC, Woods SD, et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. *Ann Surg* 1994;220:176–182.
168. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. *Ann Surg* 1999;230:170–178.
169. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. *N Engl J Med* 2002;347:1662–1669.
170. Kitajima M, Kitagawa Y. Surgical treatment of esophageal cancer—the advent of the era of individualization. *N Engl J Med* 2002;347:1705–1709.
171. Hundahl SA. Staging, stage migration, and patterns of spread in gastric cancer. *Semin Radiat Oncol* 2002;12:141–149.
172. Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials? *J Am Coll Surg* 2002;195:855–864.
173. Siewert JR, Böttcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. *Ann Surg* 1998;228:449–461.
174. Cheong O, Kim BS, Yook JH, et al. Modified radical lymphadenectomy without splenectomy in patients with proximal gastric cancer: comparison with standard D2 lymphadenectomy for distal gastric cancer. *J Surg Oncol* 2008;98:500–504.
175. Deng JY, Liang H, Sun D, et al. The most appropriate category of metastatic lymph nodes to evaluate overall survival of gastric cancer following curative resection. *J Surg Oncol* 2008;98:343–348.
176. Woodall CE III, Scoggins CR, McMasters KM, et al. Adequate lymphadenectomy results in accurate nodal staging without an increase in morbidity in patients with gastric adenocarcinoma. *Am J Surg* 2008;196:413–417.
177. Schoenleber SJ, Schnelldorfer T, Wood CM, et al. Factors influencing lymph node recovery from the operative specimen after gastrectomy for gastric adenocarcinoma. *J Gastrointest Surg* 2009;13:1233–1237.
178. Songun I, van de Velde CJ. Optimal surgery for advanced gastric cancer. *Expert Rev Anticancer Ther* 2009;9:1849–1858.
179. Songun I, van de Velde CJ. How does extended lymphadenectomy influence practical care for patients with gastric cancer? *Nat Clin Pract Oncol* 2009;6:66–67.
180. Ielpo B, Permaute AS, Elia S, et al. Impact of number and site of lymph node invasion on survival of adenocarcinoma of esophagogastric junction. *Interact Cardiovasc Thorac Surg* 2010;10:704–708.
181. Lim do H, Kim HS, Park YS, et al. Metastatic lymph node in gastric cancer: is it a real distant metastasis? *BMC Cancer* 2010;10:25.
182. Moon YW, Jeung HC, Rha SY, et al. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean institute. *Ann Surg Oncol* 2007;14:2730–2737.
183. Kodera Y, Yamamura Y, Shimizu Y, et al. The number of metastatic lymph nodes: a promising prognostic determinant for gastric carcinoma in the latest edition of the TNM classification. *J Am Coll Surg* 1998;187:597–603.
184. Methasate A, Trakarnsanga A, Akaraviputh T, et al. Lymph node metastasis in gastric cancer: result of D2 dissection. *J Med Assoc Thai* 2010;93:310–317.



185. Qureshi AP, Ottensmeyer CA, Mahar AL, et al. Quality indicators for gastric cancer surgery: a survey of practicing pathologists in Ontario. *Ann Surg Oncol* 2009;16:1883–1889.
186. Printz C. New AJCC cancer staging manual reflects changes in cancer knowledge. *Cancer* 2010;116:2–3.
187. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol* 2010;17:1471–1474.
188. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. *Br J Surg* 1988;75:110–112.
189. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. *Br J Cancer* 1999;79:1522–1530.
190. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. *N Engl J Med* 1999;340:908–914.
191. Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. *Eur J Surg Oncol* 2004;30:303–308.
192. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. *Lancet Oncol* 2006;7:309–315.
193. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. *Lancet* 1996;347:995–999.
194. Siewert JR, Böttcher K, Roder JD, et al. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. *Br J Surg* 1993;80:1015–1018.
195. Kajitani T. The general rules for the gastric cancer study in surgery and pathology: art I: clinical classification. *Jpn J Surg* 1981;11:127–139.
196. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. *Lancet Oncol* 2010;11:439–449.
197. Bonenkamp JJ, Hermans J, Sasako M, et al. Quality control of lymph node dissection in the Dutch randomized trial of D1 and D2 lymph node dissection for gastric cancer. *Gastric Cancer* 1998;1:152–159.
198. Bunt TM, Bonenkamp HJ, Hermans J, et al. Factors influencing noncompliance and contamination in a randomized trial of “Western” (r1) versus “Japanese” (r2) type surgery in gastric cancer. *Cancer* 1994;73:1544–1551.
199. Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. *Lancet* 1995;345:745–748.
200. Roggin KK, Posner MC. D3 or not D3. . . that is not the question. *Lancet Oncol* 2006;7:279–280.
201. Chen XZ, Hu JK, Zhou ZG, et al. Meta-analysis of effectiveness and safety of D2 plus para-aortic lymphadenectomy for resectable gastric cancer. *J Am Coll Surg* 2010;210:100–105.
202. Fujimura T, Nakamura K, Oyama K, et al. Selective lymphadenectomy of para-aortic lymph nodes for advanced gastric cancer. *Oncol Rep* 2009;22:509–514.
203. Brennan MF. Lymph-node dissection for gastric cancer. *N Engl J Med* 1999;340:956–958.
204. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group study 9501. *J Clin Oncol* 2004;22:2767–2773.
205. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. *N Engl J Med* 2008;359:453–462.
206. Yonemura Y, Wu CC, Fukushima N, et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. *Int J Clin Oncol* 2008;13:132–137.
207. Kulig J, Popiela T, Kolodziejczyk P, et al. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. *Am J Surg* 2007;193:10–15.
208. Cady B. Basic principles in surgical oncology. *Arch Surg* 1997;132:338–346.
209. Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. *Br J Surg* 2014;101:23–31.
210. Jiang L, Yang KH, Chen Y, et al. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. *Br J Surg* 2014;101:595–604.
211. Kodera Y, Sasako M, Yamamoto S, et al. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. *Br J Surg* 2005;92:1103–1109.
212. Furukawa H, Hiratsuka M, Ishikawa O, et al. Total gastrectomy with dissection of lymph nodes along the splenic artery: a pancreas-preserving method. *Ann Surg Oncol* 2000;7:669–673.
213. Doglietto GB, Pacelli F, Caprino P, et al. Pancreas-preserving total gastrectomy for gastric cancer. *Arch Surg* 2000;135:89–94.
214. Schwarz RE, Zagala-Navarez K. Gastrectomy circumstances that influence early postoperative outcome. *Hepatogastroenterology* 2002;49:1742–1746.
215. Schwarz RE. Spleen-preserving splenic hilar lymphadenectomy at the time of gastrectomy for cancer: technical feasibility and early results. *J Surg Oncol* 2002;79:73–76.
216. Kimura W, Yano M, Sugawara S, et al. Spleen-preserving distal pancreaticectomy with conservation of the splenic artery and vein: techniques and its significance. *J Hepatobiliary Pancreat Surg* 2009;17:813–823.
217. Yao XX, Yan C, Yan M, et al. [A comparative study on the efficacy of spleen-preserving modified D2 radical gastrectomy and D2 radical gastrectomy with splenectomy]. *Zhonghua Wei Chang Wai Ke Za Zhi* 2010;13:111–114.
218. Oh SJ, Hyung WJ, Li C, et al. The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. *J Surg Oncol* 2009;99:275–280.
219. Csendes A, Burdiles P, Rojas J, et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. *Surgery* 2002;131:401–407.
220. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. *Br J Surg* 2006;93:559–563.
221. Kunisaki C, Makino H, Suwa H, et al. Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. *J Gastrointest Surg* 2007;11:1039–1044.
222. Sano T, Yamamoto S, Sasako M. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. *Jpn J Clin Oncol* 2002;32:363–364.
223. Wang W, Li Z, Tang J, et al. Laparoscopic versus open total gastrectomy with D2 dissection for gastric cancer: a meta-analysis. *J Cancer Res Clin Oncol* 2013;139:1721–1734.
224. Coburn N, Seevaratnam R, Paszat L, et al. Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. *Ann Surg* 2014;259:102–108.
225. Kampschoer GH, Maruyama K, van de Velde CJ, et al. Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. *Br J Surg* 1989;76:905–908.
226. Bollschweiler E, Boettcher K, Hoelscher AH, et al. Preoperative assessment of lymph-node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. *Br J Surg* 1992;79:156–160.
227. Guadagni S, Catarci M, Valenti M, et al. Evaluation of the Maruyama computer program accuracy for preoperative estimation of lymph node metastases from gastric cancer. *World J Surg* 2000;24:1550–1558.
228. Hundahl SA, Macdonald JS, Benedetti J, et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. *Ann Surg Oncol* 2002;9:278–286.
229. Mekiclar J, Omejc M. Computer-guided surgery for gastric carcinoma. *Coll Antropol* 2008;32:761–766.
230. Mekiclar J, Omejc M. Preoperative prediction of lymph node status in gastric cancer patients with the help of computer analysis. *Dig Surg* 2009;26:256–261.
231. Yoo MW, Park do J, Ahn HS, et al. Evaluation of the Adequacy of lymph node dissection in pylorus-preserving gastrectomy for early gastric cancer using the maruyama index. *World J Surg* 2010;34:291–295.
232. Catarci M, Guadagni S, Zaraca F, et al. Prospective randomized evaluation of preoperative endoscopic vital staining using CH-40 for lymph node dissection in gastric cancer. *Ann Surg Oncol* 1998;5:580–284.
233. Yamagita S, Natsugoe S, Uenosono Y, et al. Sentinel node micrometastases have high proliferative potential in gastric cancer. *J Surg Res* 2008;145:238–243.
234. Arigami T, Natsugoe S, Uenosono Y, et al. Evaluation of sentinel node concept in gastric cancer based on lymph node micrometastasis determined by reverse transcription-polymerase chain reaction. *Ann Surg* 2006;243:341–347.
235. Higashi H, Natsugoe S, Uenosono Y, et al. Particle size of tin and phytate colloid in sentinel node identification. *J Surg Res* 2004;121:1–4.
236. Aikou T, Higashi H, Natsugoe S, et al. Can sentinel node navigation surgery reduce the extent of lymph node dissection in gastric cancer? *Ann Surg Oncol* 2001;8:90S–93S.
237. Kitagawa Y, Watanabe M, Hasegawa H, et al. Sentinel node mapping for colorectal cancer with radioactive tracer. *Dis Colon Rectum* 2002;45:1476–1480.
238. Kitagawa Y, Fujii H, Mukai M, et al. Radio-guided sentinel node detection for gastric cancer. *Br J Surg* 2002;89:604–608.
239. Kitagawa Y, Kitajima M. Gastrointestinal cancer and sentinel node navigation surgery. *J Surg Oncol* 2002;79:188–193.
240. Ichikura T, Morita D, Uchida T, et al. Sentinel node concept in gastric carcinoma. *World J Surg* 2002;26:318–322.
241. Miwa K, Kinami S, Taniguchi K, et al. Mapping sentinel nodes in patients with early-stage gastric carcinoma. *Br J Surg* 2003;90:178–182.
242. Miwa K, Kinami S, Taniguchi K, et al. Mapping sentinel nodes in patients with early-stage gastric carcinoma. *Gastroenterology* 2000;118:A263.
243. Hayashi H, Ochiai T, Mori M, et al. Sentinel lymph node mapping for gastric cancer using a dual procedure with dye- and gamma probe-guided techniques. *J Am Coll Surg* 2003;196:68–74.
244. Gretschel S, Bembek A, Hünerbein M, et al. Efficacy of different technical procedures for sentinel lymph node biopsy in gastric cancer staging. *Ann Surg Oncol* 2007;14:2028–2035.
245. Becher RD, Shen P, Stewart JH, et al. Sentinel lymph node mapping for gastric adenocarcinoma. *Am Surg* 2009;75:710–714.
246. Lee JH, Ryu KW, Nam BH, et al. Factors associated with detection failure and false-negative sentinel node biopsy findings in gastric cancer: results of prospective single center trials. *J Surg Oncol* 2009;99:137–142.

247. Lee SE, Lee JH, Ryu KW, et al. Sentinel node mapping and skip metastases in patients with early gastric cancer. *Ann Surg Oncol* 2009;16:603–608.
248. Kitagawa Y, Takeuchi H, Takagi Y, et al. Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan. *J Clin Oncol* 2013;31:3704–3710.
249. Miyashiro I, Hiratsuka M, Sasako M, et al. High false-negative proportion of intraoperative histological examination as a serious problem for clinical application of sentinel node biopsy for early gastric cancer: final results of the Japan Clinical Oncology Group multicenter trial JCOG0302. *Gastric Cancer* 2014;17:316–323.
250. Birkmeyer JD, Skinner JS, Wennberg DE. Will volume-based referral strategies reduce costs or just save lives? *Health Affairs* 2002;21:234–241.
251. Birkmeyer JD, Finlayson EVA. Volume and outcome - Reply. *N Eng J Med* 2002;347:693–696.
252. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. *N Eng J Med* 2002;346:1128–1137.
253. Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. *N Eng J Med* 2003;349:2117–2127.
254. Goodney PP, Stukel TA, Lucas FL, et al. Hospital volume, length of stay, and readmission rates in high-risk surgery. *Ann Surg* 2003;238:161–167.
255. Finlayson EV, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: a national study. *Arch Surg* 2003;138:721–725, discussion 726.
256. Goodney PP, Lucas FL, Birkmeyer JD. Should volume standards for cardiovascular surgery focus only on high-risk patients? *Circulation* 2003;107:384–387.
257. Hannan EL, Radzyner M, Rubin D, et al. The influence of hospital and surgeon volume on in-hospital mortality for colectomy, gastrectomy, and lung lobectomy in patients with cancer. *Surgery* 2002;131:6–15.
258. Lin HC, Xirasagar S, Lee HC, et al. Hospital volume and inpatient mortality after cancer-related gastrointestinal resections: the experience of an Asian country. *Ann Surg Oncol* 2006;13:1182–1188.
259. Birkmeyer JD, Sun Y, Goldfaden A, et al. Volume and process of care in high-risk cancer surgery. *Cancer* 2006;106:2476–2481.
260. Hollenbeck BK, Wei YL, Birkmeyer JD. High volume hospitals do not have better long term outcomes following cystectomy for bladder cancer. *J Urol* 2006;175:8.
261. Birkmeyer JD, Dimick JB, Staiger DO. Operative mortality and procedure volume as predictors of subsequent hospital performance. *Ann Surg* 2006;243:411–417.
262. Callahan MA, Christos PJ, Gold HT, et al. Influence of surgical subspecialty training on in-hospital mortality for gastrectomy and colectomy patients. *Ann Surg* 2003;238:629–636, discussion 636–639.
263. Callahan MA, Christos PJ, Gold HT, et al. Influence of surgical subspecialty training on in-hospital mortality for gastrectomy and colectomy patients. *Ann Surg* 2003;238:629–636, discussion 636–639.
264. Waljee JF, Greenfield LJ, Dimick JB, et al. Surgeon age and operative mortality in the United States. *Ann Surg* 2006;244:353–362.
265. Ritchie WP Jr, Rhodes RS, Biester TW. Work loads and practice patterns of general surgeons in the United States, 1995–1997: a report from the American Board of Surgery. *Ann Surg* 1999;230:533–542, discussion 542–543.
266. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965;64:31–49.
267. Noguchi Y, Yoshikawa T, Tsuburaya A, et al. Is gastric carcinoma different between Japan and the United States? A comparison of patient survival among three institutions. *Cancer* 2000;89:2237–2246.
268. Gill S. Ethnicity-related gastric cancer survival. In reply. *J Clin Oncol* 2003;21:4253.
269. Gill S, Shah A, Le N, et al. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a Canadian Cancer Center. *J Clin Oncol* 2003;21:2070–2076.
270. Schlemper RJ. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists (Erratum). *Lancet* 1997;350:524.
271. Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. *Lancet* 1997;349:1725–1729.
272. Schlemper RJ, Itabashi M, Kato Y, et al. Differences in the diagnostic criteria of gastric carcinoma between Japanese and Western pathologists. *Lancet* 1997;349:1725–1729.
273. Lauwers GY, Riddell RH. Gastric epithelial dysplasia. *Gut* 1999;45:784–790.
274. Lauwers GY, Shimizu M, Correa P, et al. Evaluation of gastric biopsies for neoplasia: differences between Japanese and Western pathologists. *Am J Surg Pathol* 1999;23:511–518.
275. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. *Am J Surg Pathol* 2000;24:167–176.
276. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. *Gut* 2000;47:251–255.
277. Hundahl SA. Staging, stage migration, and patterns of spread in gastric cancer. *Semi Radiat Oncol* 2002;12:141–149.
278. Bunt AM, Hermans J, Smit VT, et al. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. *J Clin Oncol* 1995;13:19–25.
279. Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? what are the suggestions? *Crit Rev Oncol Hematol* 2001;40:77–94.
280. Mezhr JJ, Pillarisetty VG, Shah MA, et al. Randomized clinical trials in gastric cancer. *Surg Oncol Clin N Am* 2010;19:81–100.
281. Huscher CG, Mingoli A, Sgarzini G, et al. Re: "laparoscopic assisted distal gastrectomy for early gastric cancer: five years' experience." *Surgery* 2005;138:543.
282. Huscher CG, Mingoli A, Sgarzini G, et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. *Ann Surg* 2005;241:232–237.
283. Kitano S, Shiraishi N, Fujii K, et al. A randomized controlled trial comparing open vs laparoscopy-assisted distal gastrectomy for the treatment of early gastric cancer: an interim report. *Surgery* 2002;131:S306–S311.
284. Hayashi H, Ochiai T, Shimada H, et al. Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer. *Surg Endosc* 2005;19:1172–1176.
285. Kim YW, Baik YH, Yun YH, et al. Improved quality of life outcomes after laparoscopy-assisted distal gastrectomy for early gastric cancer: results of a prospective randomized clinical trial. *Ann Surg* 2008;248:721–727.
286. Kim HH, Han SU, Kim MC, et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale, case-control and case-matched Korean multicenter study. *J Clin Oncol* 2014;32:627–633.
287. Ohtani H, Tamamori Y, Noguchi K, et al. A meta-analysis of randomized controlled trials that compared laparoscopy-assisted and open distal gastrectomy for early gastric cancer. *J Gastrointest Surg* 2010;14:958–964.
288. Lee JH, Han HS. A prospective randomized study comparing open vs laparoscopy-assisted distal gastrectomy in early gastric cancer: early results. *Surg Endosc* 2005;19:168–173.
289. Jiang L, Yang KH, Guan QL, et al. Laparoscopy-assisted gastrectomy versus open gastrectomy for resectable gastric cancer: an update meta-analysis based on randomized controlled trials. *Surg Endosc* 2013;27:2466–2480.
290. Liang Y, Li G, Chen P, et al. Laparoscopic versus open gastrectomy for early distal gastric cancer: a meta-analysis. *ANZ J Surg* 2011;81:673–680.
291. Kim HH, Han SU, Kim MC, et al. Prospective randomized controlled trial (phase III) to comparing laparoscopic distal gastrectomy with open distal gastrectomy for gastric adenocarcinoma (KLASS 01). *J Korean Surg Soc* 2013;84:123–130.
292. Nakamura K, Katai H, Mizusawa J, et al. A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric Cancer [JCOG0912]. *Jpn J Clin Oncol* 2013;43:324–327.
293. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med* 2007;357:1810–1820.
294. Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. *J Clin Oncol* 2011;29:4387–4393.
295. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. *Lancet* 2012;379:315–321.
296. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. *J Natl Cancer Inst* 2008;100:388–398.
297. Buyse ME, Pignon J. Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer. *J Clin Oncol* 2009;27:4539.
298. Sugarbaker PH, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. *Semin Surg Oncol* 2003;21:233–248.
299. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. *JAMA* 2010;303:1729–1737.
300. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. *Cancer* 1994;73:2048–2052.
301. Takahashi T, Hagiwara A, Shimotsu M, et al. Prophylaxis and treatment of peritoneal carcinomatosis: intraperitoneal chemotherapy with mitomycin C bound to activated carbon particles. *World J Surg* 1995;19:565–569.
302. Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. *Cancer* 1999;85:529–534.
303. Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. *HepatoGastroenterology* 2001;48:1776–1782.
304. Rosen HR, Jatzko G, Repse S, et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. *J Clin Oncol* 1998;16:2733–2738.
305. Yu W, Whang I, Suh I, et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. *Ann Surg* 1998;228:347–354.
306. Yu W, Whang I, Chung HY, et al. Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. *World J Surg* 2001;25:985–990.

307. Wei G, Fang GE, Bi JW, et al. [Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer]. *Ai Zheng* 2005;24:478–482.
308. Sautner T, Hofbauer F, Depisch D, et al. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. *J Clin Oncol* 1994;12:970–974.
309. Xu DZ, Zhan YQ, Sun XW, et al. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. *World J Gastroenterol* 2004;10:2727–2730.
310. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. *Ann Surg Oncol* 2007;14:2702–2713.
311. Kang Y, Chang H, Zang D, et al. Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: A randomized phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxorifuridine plus cisplatin (iceMFP) versus mitomycin-C plus short-term doxorifuridine (Mf) (AMC 0101) (NCT00296322). *J Clin Oncol* 2008;26:LB4511.
312. Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. *Ann Surg* 2009;250:242–246.
313. Kelsen D, Karpeh M, Schwartz G, et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. *J Clin Oncol* 1996;14:1818–1828.
314. Brenner B, Shah MA, Karpeh MS, et al. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal fluorouracil-leucovorin in patients with locally advanced gastric cancer. *Ann Oncol* 2006;17:1404–1411.
315. Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. *J Clin Oncol* 2003;21:428–432.
316. Minamimoto R, Senda M, Jinnouchi S, et al. Performance profile of a FDG-PET cancer screening program for detecting gastric cancer: results from a nationwide Japanese survey. *Jpn J Radiol* 2014;32:253–259.
317. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 2006;355:11–20.
318. Boige V, Pignon J, Saint-Aubert B, et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. *J Clin Oncol* 2007;25:4510.
319. Liao Y, Yang ZL, Peng JS, et al. Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. *J Gastroenterol Hepatol* 2013;28:777–782.
320. Allum WH, Hallissey MT, Ward LC, et al. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. *Br J Cancer* 1989;60:739–744.
321. Hallissey MT, Dunn JA, Ward LC, et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. *Lancet* 1994;343:1309–1312.
322. Zhang ZX, Gu XZ, Yin WB, et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)—report on 370 patients. *Int J Radiat Oncol Biol Phys* 1998;42:929–934.
323. Ohri N, Garg MK, Aparo S, et al. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. *Int J Radiat Oncol Biol Phys* 2013;86:330–335.
324. Liao Y, Yang ZL, Peng JS, et al. Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. *J Gastroenterol Hepatol* 2013;28:777–782.
325. Gunderson L, Willet G, Harrison B, et al., eds. *Intraoperative Irradiation: Techniques and Results*. Totowa, NJ: Humana Press; 1999.
326. Abe M, Takahashi M, Ono K, et al. Japan gastric trials in intraoperative radiation therapy. *Int J Radiat Oncol Biol Phys* 1988;15:1431–1433.
327. Sindelar WF, Kinsella TJ, Tepper JE, et al. Randomized trial of intraoperative radiotherapy in carcinoma of the stomach. *Am J Surg* 1993;165:178–186, discussion 186–187.
328. Dent DM, Werner ID, Novis B, et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. *Cancer* 1979;44:385–391.
329. Moertel CG, Childs DS, O'Fallon JR, et al. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. *J Clin Oncol* 1984;2:1249–1254.
330. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 2001;345:725–730.
331. Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. *J Clin Oncol* 2011;29:4003.
332. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. *J Clin Oncol* 2012;30:268–273.
333. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. *N Engl J Med* 1996;335:462–467.
334. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. *J Clin Oncol* 2008;26:1086–1092.
335. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. *J Clin Oncol* 2009;27:851–856.
336. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. *J Clin Oncol* 2004;22:2774–2280.
337. Ajani JA, Mansfield PF, Crane CH, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. *J Clin Oncol* 2005;23:1237–1244.
338. Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 2006;24:3953–3958.
339. Mohri Y, Tonouchi H, Kobayashi M, et al. Randomized clinical trial of single- versus multiple-dose antimicrobial prophylaxis in gastric cancer surgery. *Br J Surg* 2007;94:683–688.
340. Doglietto GB, Papa V, Tortorelli AP, et al. Nasojejunal tube placement after total gastrectomy: a multicenter prospective randomized trial. *Arch Surg* 2004;139:1309–1313, discussion 1313.
341. Yoo CH, Son BH, Han WK, et al. Nasogastric decompression is not necessary in operations for gastric cancer: prospective randomised trial. *Eur J Surg* 2002;168:379–383.
342. Lee JH, Hyung WJ, Noh SH. Comparison of gastric cancer surgery with versus without nasogastric decompression. *Yonsei Med J* 2002;43:451–456.
343. Yang Z, Zheng Q, Wang Z. Meta-analysis of the need for nasogastric or nasojejunal decompression after gastrectomy for gastric cancer. *Br J Surg* 2008;95:809–816.
344. Kim J, Lee J, Hyung WJ, et al. Gastric cancer surgery without drains: a prospective randomized trial. *J Gastrointest Surg* 2004;8:727–732.
345. Alvarez Usilar R, Molina H, Torres O, et al. Total gastrectomy with or without abdominal drains. A prospective randomized trial. *Rev Esp Enferm Dig* 2005;97:562–569.
346. Iivonen MK, Koskinen MO, Ikonen TJ, et al. Emptying of the jejunal pouch and Roux-en-Y limb after total gastrectomy—a randomised, prospective study. *Eur J Surg* 1999;165:742–747.
347. Fein M, Fuchs KH, Thalheimer A, et al. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. *Ann Surg* 2008;247:759–765.
348. Smalley SR, Gunderson L, Tepper J, et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. *Int J Radiat Oncol Biol Phys* 2002;52:283–293.
349. Tepper JE, Gunderson LL. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. *Semin Radiat Oncol* 2002;12:187–195.
350. Gilbertson V. Results of treatment of stomach cancer. An appraisal of efforts for more extensive surgery and a report of 1938 cases. *Cancer* 1969;23:1305–1308.
351. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. *Int J Radiat Oncol Biol Phys* 1982;8:1–11.
352. McNeer G, Vandenberg H Jr, Donn FY, et al. A critical evaluation of subtotal gastrectomy for the cure of cancer of the stomach. *Ann Surg* 1951;134:2–7.
353. Stout AP. Pathology of carcinoma of the stomach. *Arch Surg* 1943;46:807–822.
354. Henning GT, Schild SE, Stafford SL, et al. Results of irradiation or chemoradiation following resection of gastric adenocarcinoma. *Int J Radiat Oncol Biol Phys* 2000;46:589–598.
355. Gunderson LL, Hoskins RB, Cohen AC, et al. Combined modality treatment of gastric cancer. *Int J Radiat Oncol Biol Phys* 1983;9:965–975.
356. Regine WF, Mohiuddin M. Impact of adjuvant therapy on locally advanced adenocarcinoma of the stomach. *Int J Radiat Oncol Biol Phys* 1992;24:921–927.
357. A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group. *Cancer* 1982;49:1771–1777.
358. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced cancer. *Cochrane Database Syst Rev* 2010;(3):CD004064.
359. Thuss-Patience PC, Kretzschmar A, Deist T, et al. Irinotecan versus best supportive care as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *J Clin Oncol* 2009;27:Abstr 4540.
360. Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. *Ann Oncol* 2009;20:1529–1534.
361. Di Cosimo S, Ferretti G, Fazio N, et al. Docetaxel in advanced gastric cancer—review of the main clinical trials. *Acta Oncol* 2003;42:693–700.



362. Cunningham D, Rao S, Starling N, et al. Randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL-2 trial. *J Clin Oncol* 2006;24:LBA4017.
363. Vanhoefler U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. *J Clin Oncol* 2000;18:2648–2657.
364. Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). *J Clin Oncol* 2003;21:54–59.
365. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006;24:4991–4997.
366. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. *Ann Oncol* 2008;19:1450–1457.
367. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial. *Ann Oncol* 2009;20:666–673.
368. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLACS trial. *J Clin Oncol* 2010;28:1547–1553.
369. Shah MA, Stoller R, Shibata S, et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). *J Clin Oncol* 2010;28:Abstr 4014.
370. Pozzo C, Barone C, Szanto J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. *Ann Oncol* 2004;15:1773–1781.
371. Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. *J Clin Oncol* 2002;20:1996–2004.
372. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. *J Clin Oncol* 2006;24:5201–5206.
373. Nardi M, Azzarello D, Maisano R, et al. FOLFOX-4 regimen as first-line chemotherapy in elderly patients with advanced gastric cancer: a safety study. *J Chemother* 2007;19:85–89.
374. Cunningham D, Okines AF, Ashley S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med* 2008;358:36–46.
375. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26:1435–1442.
376. Catalano V, Graziano F, Santini D, et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? *Br J Cancer* 2008;99:1402–1407.
377. Lee J, Lim T, Uhm JE, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. *Ann Oncol* 2007;18:886–891.
378. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Eur J Cancer* 2011;47:2306–2314.
379. Park SH, Lim DH, Park K, et al. A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). *J Clin Oncol* 2011;29:Abstr 4004.
380. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. *J Clin Oncol* 2013;31:4438–4444.
381. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced cancer (GC). *J Clin Oncol* 2009;27:Abstr LBA450.
382. Bang Y, Chung H, Sawaki A, et al. HER2-positivity rates in advanced gastric cancer (GC): results from a large international phase III trial. *J Clin Oncol* 2008;26:Abstr 4526.
383. Lordick F, Luber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Br J Cancer* 2010;102:500–505.
384. Kubo T, Kuroda Y, Shimizu H, et al. Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer. *Carcinogenesis* 2009;30:1857–1864.
385. Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST: a randomized, double blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer. *J Clin Oncol* 2010;28:LBA4007.
386. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. *J Clin Oncol* 2005;23:2574–2576.
387. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. *J Clin Oncol* 2011;29:3968–3976.
388. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. *J Clin Oncol* 2012;30:2119–2127.
389. Bang Y, Kang Y, Kang W, et al. Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer. *Eur J Cancer Suppl* 2007;5:272.
390. Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. *J Clin Oncol* 2013;31:3219–3225.
391. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucicromab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicenter, placebo-controlled, phase 3 trial. *Lancet* 2014;383:31–39.
392. Okamoto I, Doi T, Ohtsu A, et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. *Jpn J Clin Oncol* 2010;40:17–23.
393. Takiuchi H, Doi T, Muro K, et al. Everolimus in patients with previously treated metastatic gastric cancer: Final results of a multicenter Phase II study. *J Clin Oncol* 2010.
394. Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. *J Clin Oncol* 2010;28:1904–1910.
395. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. *J Clin Oncol* 1998;16:309–316.
396. Ooi CH, Ivanova T, Wu J, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. *PLoS Genet* 2009;5:e1000676.
397. Kim HK, Choi JJ, Kim CG, et al. Gene expression signatures to predict the response of gastric cancer to cisplatin and fluorouracil. *J Clin Oncol* 2009;27:Abstr 4628.
398. Janjigian Y, Kelsen DP, Ilson D, et al. HER2 status of patients with gastric cancer (GC) in the United States. *J Clin Oncol* 2010;27:Abstr 30.
399. Shah MA, Yeung H, Coit D, et al. A phase II study of preoperative chemotherapy with irinotecan (CPT) and cisplatin (CIS) for gastric cancer (NCI 5917): FDG-PET/CT predicts patient outcome. *J Clin Oncol* 2007;25:4502.
400. Weber WA. Chaperoning drug development with PET. *J Nucl Med* 2006;47:735–737.
401. Kerkar SP, Kemp CD, Duffy A, et al. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone. *Trials* 2009;10:121.
402. Kerkar SP, Kemp CD, Avital I. Liver resections for metastatic gastric cancer. *HPB (Oxford)* 2010;12:589–596.
403. Kemp CD, Kerkar KM, Ripley TR, et al. Pulmonary resection for metastatic gastric cancer. *J Thorac Oncol* 2010;5:1796–1805.
404. Okajima K, Yamada S. [Surgical treatment of far-advanced gastric cancer]. *Gan No Rinsho* 1986;32:1203–1209.
405. Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. *Oncology* 2000;58:96–107.
406. Boku T, Nakane Y, Minoura T, et al. Prognostic significance of serosal invasion and free intraperitoneal cancer cells in gastric cancer. *Br J Surg* 1990;77:436–439.
407. Moriguchi S, Maehara Y, Korenaga D, et al. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. *Surg Oncol* 1992;1:341–346.
408. Roviello F, Marrelli D, de Manzoni G, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. *Br J Surg* 2003;90:1113–1119.
409. Maehara Y, Hasuda S, Koga T, et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. *Br J Surg* 2000;87:353–357.
410. Lee CC, Lo SS, Wu CW, et al. Peritoneal recurrence of gastric adenocarcinoma after curative resection. *Hepatogastroenterology* 2003;50:1720–1722.
411. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. *Cancer* 2000;88:358–363.

412. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in non-gynecologic malignancy. A prospective study of prognostic factors. *Cancer* 1989;63:364–367.
413. Yamada S, Takeda T, Matsumoto K. Prognostic analysis of malignant pleural and peritoneal effusions. *Cancer* 1983;51:136–140.
414. Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. *Ann Surg Oncol* 2010;17:2370–2377.
415. Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. *Br J Surg* 2005;92:370–375.
416. Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. *J Gastrointest Surg* 2004;8:454–463.
417. Brigand C, Arvieux C, Gilly FN, et al. Treatment of peritoneal carcinomatosis in gastric cancers. *Dig Dis* 2004;22:366–373.
418. Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. *Arch Surg* 2004;139:20–26.
419. Ajani JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. *Cancer* 1991;67:260–265.
420. Kusamura S, Baratti D, Younan R, et al. The Delphi approach to Attain consensus in methodology of local regional therapy for peritoneal surface malignancy. *J Surg Oncol* 2008;98:217–219.
421. Baratti D, Kusamura S, Deraco M. The Fifth International Workshop on Peritoneal Surface Malignancy (Milan, Italy, December 4–6, 2006): methodology of disease-specific consensus. *J Surg Oncol* 2008;98:258–262.
422. Younan R, Kusamura S, Baratti D, et al. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. *J Surg Oncol* 2008;98:253–257.
423. Gonzalez-Moreno S, Kusamura S, Baratti D, et al. Postoperative residual disease evaluation in the locoregional treatment of peritoneal surface malignancy. *J Surg Oncol* 2008;98:237–241.
424. Verwaal VJ, Kusamura S, Baratti D, et al. The eligibility for local-regional treatment of peritoneal surface malignancy. *J Surg Oncol* 2008;98:220–223.
425. Canbay E, Mizumoto A, Ichinose M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. *Ann Surg Oncol* 2014;21:1147–1152.
426. Ekbohm CA, Gleysteen JJ. Gastric malignancy: resection for palliation. *Surgery* 1980;88:476–481.
427. Meijer S, De Bakker OJ, Hoitsma HF. Palliative resection in gastric cancer. *J Surg Oncol* 1983;23:77–80.
428. Butler JA, Dubrow TJ, Trezona T, et al. Total gastrectomy in the treatment of advanced gastric cancer. *Am J Surg* 1989;158:602–604, discussion 604–605.
429. Bozzetti F, Doci P, Bignami P, et al. Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach. *Ann Surg* 1987;205:264–270.
430. Bozzetti F, Bonfanti G, Audisio RA, et al. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. *Surg Gynecol Obstet* 1987;164:151–154.
431. Boddie AW Jr, McMurtrey MJ, Giacco GG, et al. Palliative total gastrectomy and esophagogastrectomy: a reevaluation. *Cancer* 1983;51:1195–1200.